Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
Real-world and subgroup evidence for patients like their own: 60.1% of US physicians and other prescribers on the Brox HCP panel name it as what they most want from a medical science liaison that a sales rep cannot give, and 65.2% rate a 20-minute liaison meeting at least moderately useful against 17.7% for a rep meeting (n=198, November 2026).
- Who was asked
- HCP, 198 clones, US
- When
- November 2026 (fielded 18 November 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question asks what liaisons are for. We asked 198 clones of US prescribers to rate a 20-minute meeting with each kind of contact on the same five-point scale, to pick the one thing they want from a liaison that a rep cannot give, and to choose a follow-up when a rep cannot answer a clinical question. That turns a list of roles into shares a medical affairs team can plan against.
Section 01: What the panel said
- #
65.2%
65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine
base 198
- #
60.1%
60.1% most want real-world and subgroup data for patients like theirs from a liaison; 23.7% want answers to off-label or unpublished data questions, and 13.1% say a rep and the published papers already give them what they need
base 198
- #
18.2%
18.2% would choose a liaison call within a week when a rep cannot answer a clinical question; 53.0% would rather have a link to the paper or the label section and 28.3% would look it up themselves
base 198 · contrast
- #
16
16 of 25 clones who rate a liaison meeting very or extremely useful would take the liaison call, against 20 of the other 173
base 25 · Clones rating a liaison meeting very or extremely useful · contrast
65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine
02How far apart are a liaison meeting and a rep meeting?
Far apart, and on the same clones. Each clone rated a 20-minute meeting with a sales representative and a 20-minute meeting with a medical science liaison on the same five-point scale, and 75.8% (150 of 198) rated the liaison meeting higher. Only 5 of 198 rated it lower.
The rep meeting is mostly dismissed: 82.3% (163 of 198) call it slightly useful or not useful at all, and no clone calls it extremely useful. The liaison meeting sits in the middle of the scale rather than at the top: 52.5% call it moderately useful and 12.1% very useful.
03Does the answer change outside dermatology?
Not much. Among the 126 dermatologists, 65.9% rate the liaison meeting at least moderately useful against 14.3% for the rep meeting. Among the 72 other prescribers, it is 63.9% against 23.6%: the rep does a little better outside dermatology, and the liaison does just as well.
Real-world and subgroup data is the leading want in both groups (76 of 126 dermatologists, 43 of 72 others), and the share who would take a liaison call within a week is the same in both, 18.3% and 18.1%.
04Why do so few prescribers want a liaison to call them back?
Because the call was a week away and a link is instant. When a rep cannot answer a clinical question, 81.3% (161 of 198) would rather serve themselves: 53.0% want a link to the paper or the label section and 28.3% would look it up with no follow-up at all. The written medical information letter is chosen by 1 of 198.
What the numbers support is narrower than it first looks: a one-week wait loses to a link. The interesting reading is that prescribers value a liaison as a scheduled source of evidence, not as a callback service: 16 of the 25 clones who rate a liaison meeting very or extremely useful would take the call, against 20 of the other 173.
05What would a medical affairs lead do with this?
- A reading, not the panel's answer: build liaison meetings around real-world and subgroup evidence for the prescriber's own patient mix, since that is what 60.1% (n=198) say a rep cannot give them.
- A second reading: answer an unanswerable rep question with a link to the paper or the label the same day, and offer the liaison conversation as a follow-on rather than the first reply.
06What else do people ask about medical science liaisons?
- What share of physicians find a medical science liaison meeting useful? 65.2% of US physicians and other prescribers on the Brox HCP panel rate a 20-minute liaison meeting at least moderately useful, against 17.7% for a sales rep meeting (n=198, November 2026).
- What do physicians most want from an MSL that a rep cannot give? Real-world and subgroup data for patients like theirs, picked by 60.1%, ahead of answers to off-label or unpublished data questions at 23.7% (n=198).
- How many physicians want an MSL call when a rep cannot answer their question? 18.2% would choose a liaison call within a week, while 53.0% would rather have a link to the paper or label (n=198).
Section 07: What they said, and the interview line it rests on
“I would consider that moderately useful. Since it's a medication I already prescribe, I'm already familiar with its day-to-day clinical profile, dosing, and how my patients respond. Plus, seeing around 45 patients a day means a 20-minute meeting is a significant commitment. That being said, unlike commercial sales reps who are just pitching a product, an MSL brings actual scientific data, deeper mechanistic insights, and updated safety or trial analysis. I value looking closely at data and understanding therapies at a deeper level to grow as a clinician, so hearing about new clinical nuances or emerging safety data from a medical scientist is worthwhile, even if it doesn't fundamentally overhaul how I'm already using the drug.”
Predicted from this line in the interview
“if reps will come to our clinic, they're allowed to come to our clinic and they will bring us information, but they're never the source of truth. that's not where I get my information. I usually have already heard about it before they come.”
“For me, the most valuable thing an MSL could provide is real-world and subgroup data for patients like mine. In academic dermatology, and specifically working with a diverse, underserved patient population and skin of color, one of my biggest frustrations with standard clinical trial packages is how underrepresented diverse demographics often are. When a drug launches or is being discussed, a sales rep just gives you the standard promotional deck. But I need to know: what patient demographics were actually included in the study? How does this medication perform across different skin types and real-world comorbidity profiles? Having access to genuine real-world evidence and granular subgroup data helps me understand whether a therapy will actually work safely and effectively for my specific patient panel.”
Predicted from this line in the interview
“I want to see how the clinical trial was done. What patient demographic was in the clinical trial? I want to see are there any real world studies out there?”
“Just send me a link to the published paper or the label section. I don't need an MSL calling me or taking up my time, and I don't really find promotional summaries or company letters helpful since they're usually biased. I prefer to review the actual randomized controlled trial data and academic literature directly to evaluate the safety and efficacy myself.”
Predicted from this line in the interview
“Like looking at like randomized controlled trial data like I just try to find the most unbiased data I can.”
Section 08: How much should you trust this?
What we would defend
- The gap between the two meetings holds in both groups: 65.9% against 14.3% among the 126 dermatologists and 63.9% against 23.6% among the 72 other prescribers.
- It holds clone by clone: 150 of 198 rated the liaison meeting higher than the rep meeting on the same scale, and 5 rated it lower.
- Real-world and subgroup data is the leading want in both groups (76 of 126 dermatologists, 43 of 72 others).
What we would not
- The size of the gap. The liaison question described the liaison as a scientist who does not promote products and the rep question carried no description, so part of the 65.2% against 17.7% may be the wording.
- The 18.2% as a measure of interest in liaisons. It is the share who would wait up to a week for a call rather than take an instant link; 116 of 198 answers reason from the week.
- Any figure by age, gender or state: those details are missing for most of these clones.
- A national figure for all US prescribers: this panel is two-thirds dermatologists.
The main limitation
Almost every answer (196 to 198 of 198 on each question) was inferred from what each person said in interview about reps, medical affairs and evidence, rather than from an answer to this exact question, so read the figures as this panel's direction, not a national estimate.
Section 09: How was this run?
| Segment | Clones |
|---|---|
| Dermatology | 126 |
| Another medical specialty | 46 |
| Primary care | 17 |
| Nurse practitioner, physician assistant or pharmacist | 6 |
| Surgical specialty | 3 |
Question wording as fielded
- In general, which ONE of these would you most want from a pharmaceutical company's medical science liaison (MSL), a scientist on its medical affairs team who does not promote products, that the company's sales representative cannot give you?
- A pharmaceutical company's sales representative asks for a 20-minute meeting about a medicine you already prescribe. How useful would that meeting be to your clinical practice?
- A pharmaceutical company's medical science liaison (MSL), a scientist on its medical affairs team who does not promote products, asks for a 20-minute meeting about a medicine you already prescribe. How useful would that meeting be to your clinical practice?
- You ask a pharmaceutical company's sales representative a clinical question about a medicine that the representative is not allowed to answer. Which ONE follow-up would you prefer?
What was not asked, and why
We named no company, medicine or therapy area, and did not ask how often prescribers meet liaisons or whether a liaison has changed a prescribing decision. Specialty was not asked again: it comes from the same 198 clones' answers in an earlier study. Ask Brox added one screening question on prescribing authority, which all 198 passed.
What changed from the obvious question
The obvious question asks what liaisons are for. We asked 198 clones of US prescribers to rate a 20-minute meeting with each kind of contact on the same five-point scale, to pick the one thing they want from a liaison that a rep cannot give, and to choose a follow-up when a rep cannot answer a clinical question. That turns a list of roles into shares a medical affairs team can plan against.
Fielded through Ask Brox on 18 November 2026.
More on How doctors decide what to prescribe · Pharma & HCP · HCP (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
37.1% 37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. (base 70)
Read -
New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
22.9% 22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. (base 70)
Read -
Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
66.7% Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. (base 198)
Read -
Oral JAK inhibitor or biologic: 88.9% of US dermatologists start a pill-seeking eczema patient on the JAK, and only a $150 a month gap tips most to the biologic
88.9% For a healthy 35-year-old with moderate-to-severe eczema who dislikes injections and asks for a pill, 88.9% of US dermatologists would start an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month; 81.7% still would when the JAK costs $30 a month more, 69.0% at $75 more and 46.8% at $150 more. (base 126)
Read